Compounds > quinoxalines
Page last updated: 2024-08-17

quinoxalines and Central Serous Retinopathy

quinoxalines has been researched along with Central Serous Retinopathy in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Claiborne, RT; Tsan, GL1
Akapame, S; Burgess, EF; Duran, I; Fleming, MT; García-Donas, J; Huddart, RA; Joshi, M; Loriot, Y; Mellado, B; Monga, M; Necchi, A; O'Hagan, A; Park, SH; Rezazadeh Kalebasty, A; Santiago-Walker, AE; Siefker-Radtke, AO; Tagawa, ST; Varlamov, S; Zakharia, Y1

Trials

1 trial(s) available for quinoxalines and Central Serous Retinopathy

ArticleYear
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
    The Lancet. Oncology, 2022, Volume: 23, Issue:2

    Topics: Aged; Carcinoma, Transitional Cell; Central Serous Chorioretinopathy; ErbB Receptors; Follow-Up Studies; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms

2022

Other Studies

1 other study(ies) available for quinoxalines and Central Serous Retinopathy

ArticleYear
Case Report: Erdafitinib-induced Central Serous Chorioretinopathy.
    Optometry and vision science : official publication of the American Academy of Optometry, 2022, 01-01, Volume: 99, Issue:1

    Topics: Aged, 80 and over; Carcinoma, Transitional Cell; Central Serous Chorioretinopathy; Female; Humans; Male; Protein Kinase Inhibitors; Pyrazoles; Quality of Life; Quinoxalines; Receptors, Fibroblast Growth Factor; United States; Urinary Bladder Neoplasms

2022